Video

Linda S. Lee, MD, Talks About Using AI During DDW 2023

Author(s):

Recent studies have indicated that using adenoma per colonoscopy as a metric could help better forecast the risk of colon cancer.

The explosion of artificial intelligence has permeated through basically all walks of life, including medicine.

In an abstract presented during the 2023 Digestive Disease Week (DDW) in Chicago, a group of investigators focused on using artificial intelligence to help better detect a significantly higher number of adenomas following colonoscopies.

In the study, investigators used the CAD-Eye system to detect polyps in patients aged 45 years and older.

The results of the 1033 person study show the computer assisted colonoscopy resulted in a significantly higher adenoma per colonoscopy (APC) compared to the standard colonoscopy.

In an interview with HCPLive®, Linda S. Lee, MD, Director of Endoscopy, Brigham and Women’s Hospital, explained how the results show utilizing artifical intelligence could be a way to better increase accuracy in cancer screenings.

“Basically what we found is there is a significantly higher APC detection when the CAD-Eye system was used compared to patients who had undergone standard colonoscopy,” she said. “I believe it may be one of the only studies looking at the use of AI in colonoscopy with using this newer quality indicator called APC.”

Lee said recent studies have shown that APC maybe better than ADR in showing which patients will not develop interval colon cancer over the next 3 years following a colonoscopy.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.